Nephrology

Check out perspective from a pair of ASN Kidney Week 2023 interviews with leading trialists discussing the evolution of cardiovascular-kidney-metabolic syndrome and how pharmacotherapy has propelled the growing recognition.

Results called attention to a greater risk of hospitalization among patients with CKD who exhibited depressive symptoms, regardless of treatment with dialysis.

Data presented at ASN Kidney Week 2023 highlighted the patient-reported difficulty of implementing physician-recommended lifestyle changes but noted significant impacts on physical health, mental health, and overall quality of life when done successfully.

At ASN Kidney Week 2023, we collected perspectives from 10 key opinion leaders in nephrology on what they see as the most significant news in their specialty from the past year.

Results presented at ASN Kidney Week 2023 highlighted the importance of eGFR and albuminuria measurements for identifying risk of major adverse kidney disease events.

Richard Johnson, MD, discusses the results of a study from ASN Kidney Week 2023 detailing the effects of urate-lowering therapy on blood pressure among patients with gout.

An analysis of data from 26 patients with repeat kidney biopsies in the AURORA program suggests voclosporin (Lupkynis) reduces proteinuria without causing harm in lupus nephritis patients.

The study, presented at ASN Kidney Week 2023, sought to assess the impact of sociodemographic stress on outcomes in home dialysis among patients with ESRD.

Patrick Rossignol, MD, PhD, provides additional perspective on the results of the ALCHEMIST trial from Kidney Week 2023.

Food insecurity was associated with more missed appointments and fluid or electrolyte-related hospitalizations among patients on hemodialysis, especially those under 55 years of age.

Joanthan Barratt, MD, discusses the results of a RaDaR analysis aimed at examining trends in time-averaged proteinuria and eGFR slope in patients with IgA nephropathy.

Findings presented at ASN Kidney Week 2023 highlighted an association between distance to the transplant center and increased clinic cancellations.

Michelle Rheault, MD, provides additional perspective on the results of the DUPLEX trial, which examined sparsentan in patients with FSGS.

Data presented at ASN Kidney Week 2023 suggested male kidney donors recover greater kidney function than females after donation.

Data for a pair of studies presented at Kidney Week 2023 provide an overview of the effects of eGFR and how this might translate to potential long-term benefit in patients IgA nephropathy.

We sat down with Maya Clark-Cutaia, RN, MSN, PhD, assistant professor of nursing at New York University Rory Meyers College of Nursing to discuss disparities in the kidney transplantation process and how they should be addressed in future efforts.

Data from multiple presentations at ASN Kidney Week 2023 offer insight into the effects of atacicept in patients with IgA nephropathy as well as the design of the phase 3 trial, which is currently enrolling.

Results presented in an abstract at ASN Kidney Week 2023 showed White patients had the greatest access to waitlisting and transplantation.

We sat down with Amit Garg, MD, PhD, to discuss results from the EnAKT LKD trial and the development of a multicomponent intervention model for increasing access to kidney transplantation

Analysis of nearly 15k patients with non-dialysis-dependent CKD and anemia provides insight into contemporary trends in management.

Preliminary data from the open-label RUBY-3 trial were presented at the American Society of Nephrology Kidney Week 2023.

Oliver Gross, MD, discusses the unmet need in Alport Syndrome and the implications of study results presented at ASN Kidney Week 2023.

EnAKT LKD was conducted across 26 CKD programs in Ontario Canada, offering a multi-component intervention designed to target several barriers thought to prevent kidney transplantation and living donation - however, results showed no significant difference between the intervention and usual care groups.

Results of the ZENITH-CKD trial provide evidence of the safety and efficacy profile of combination zibotentan plus dapagliflozin in patients with chronic kidney disease.

Primary results presented at ASN Kidney Week 2023 showed spironolactone missed the trial's primary endpoint.

The 2-year data from the PROTECT study confirms the sustained benefit of sparsentan in patients with IgA nephropathy.

Aldosterone synthase inhibition dose-dependently reduced albuminuria by up to 40% in participants with CKD, according to study results presented at ASN Kidney Week 2023.

Although the DUPLEX trial missed its primary endpoint of eGFR slope in patients with FSGS, results point to greater reductions in proteinuria and in risk of kidney failure with sparsentan use relative to irbesartan—making its case for becoming a standard of care for the glomerular disease.

Data presented at ASN Kidney Week 2023 described the effects of SGLT2 inhibition in young patients with Alport syndrome.

An analysis of Target-HTN provides new insight into the effects of lorundrostat among patients with uncontrolled or treatment-resistant hypertension.